Barry Migicovsky, MD
Gastroenterology · Boulder, CONPI 1316948797
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $173,050 of the $206,071 with a category attached, or 84.0%. 40 manufacturers reported payments, led by Madrigal Pharmaceuticals at 32.6% of the total. Among gastroenterology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 852 payments — averaging $241.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Madrigal Pharmaceuticals$67K
- Gilead$61K
- AbbVie$35K
- Phathom Pharmaceuticals, Inc.$28K
- Intercept Pharmaceuticals, Inc.$5K
- Olympus Corporation$2K
- plus $7K from 34 others
Across 2 payments — averaging $1347.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$3K
What the payments were for
- Consulting fees$2,3101%
- Speaking & faculty fees$173,05084%
- Travel & lodging$12,2216%
- Food & beverage$18,3739%
- Education$1170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$206,071 in reported general payments places this provider in the 95th percentile of 304 gastroenterology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 12 | $334,286 |
| Humira PenAdalimumab | 12 | $171,127 |
| CreonLipase/Protease/Amylase | 26 | $97,659 |
| ZenpepLipase/Protease/Amylase | 17 | $76,989 |
| SucraidSacrosidase | 11 | $76,050 |
| XifaxanRifaximin | 21 | $66,229 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 201 | $34,119 |
| LinzessLinaclotide | 22 | $29,502 |
| Mesalamine | 16 | $7,434 |
| Entecavir | 17 | $6,298 |
| Dexlansoprazole DrDexlansoprazole | 13 | $5,908 |
| Omeprazole | 312 | $4,109 |
| Balsalazide Disodium | 16 | $2,638 |
| Colestipol Hcl | 18 | $2,327 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 36 | $2,205 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $939 | $334,28612 claims |
| AbbVieCreon, Linzess | $35,261 | $127,16148 claims |
| Aimmune Therapeutics, Inc.Zenpep | $110 | $76,98917 claims |
| QOL Medical, LLCSucraid | $600 | $76,05011 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $1,045 | $66,22921 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $245 | $34,119201 claims |
| Braintree Laboratories, Inc.Sutab | $136 | $1,75111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 304 gastroenterology providers in Colorado.
Other gastroenterology in Boulder
- Peter McNallyFt Carson$1.1M
- Douglas AdlerColorado Springs$910K
- Marcelo KugelmasEnglewood$660K
- Mary Ann HuangDenver$408K
- Gareth WeinerThornton$382K
- Matthew NicholsLone Tree$360K
- Nathan SchomakerLone Tree$344K
- Joshua SteinbergNorthglenn$266K
- Rajesh JainLakewood$239K
- Mihir WaghAurora$217K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.